1. Home
  2. BFST vs LBRX Comparison

BFST vs LBRX Comparison

Compare BFST & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Business First Bancshares Inc.

BFST

Business First Bancshares Inc.

HOLD

Current Price

$28.48

Market Cap

877.1M

Sector

Finance

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

HOLD

Current Price

$29.40

Market Cap

850.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFST
LBRX
Founded
2006
2015
Country
United States
United States
Employees
N/A
27
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
877.1M
850.5M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
BFST
LBRX
Price
$28.48
$29.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
5
Target Price
$32.75
$46.60
AVG Volume (30 Days)
151.2K
134.2K
Earning Date
04-27-2026
05-06-2026
Dividend Yield
2.23%
N/A
EPS Growth
23.45
N/A
EPS
0.68
N/A
Revenue
$10,704,000.00
N/A
Revenue This Year
$22.71
N/A
Revenue Next Year
$5.02
N/A
P/E Ratio
$41.84
N/A
Revenue Growth
1.20
N/A
52 Week Low
$22.56
$13.40
52 Week High
$30.32
$33.47

Technical Indicators

Market Signals
Indicator
BFST
LBRX
Relative Strength Index (RSI) 58.65 51.30
Support Level $26.73 $22.39
Resistance Level $29.44 $33.47
Average True Range (ATR) 0.55 1.51
MACD 0.08 -0.00
Stochastic Oscillator 86.32 72.46

Price Performance

Historical Comparison
BFST
LBRX

About BFST Business First Bancshares Inc.

Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Share on Social Networks: